WHO WE ARE
We get the right drug, to the right patient, at the right time.
To fundamentally change how diseases are diagnosed and treated. With our pioneering metabolomics platform and machine learning algorithms we produce “Biomarkers of Response” (BoR) to readily differentiate drug responders (R) from non-responders (NR).
Our primary focus is in metastatic breast cancer where the need to differentiate R vs NR is often life and death. We are developing products to arm breast cancer patients to combat cancer and live their best lives.